Slow Coagulation TSCPC for Postvitrectomy Patients With Sili
Slow coagulation transscleral cyclophotocoagulation (TSCPC) is an effective and safe glaucoma surgery in patients with medically uncontrolled silicone oil (SO)-induced glaucoma.

The purpose of this study was to report the outcomes of slow coagulation continuous wave TSCPC in patients with medically uncontrolled secondary glaucoma following pars plana vitrectomy (PPV) and intravitreal SO injection.

This retrospective study enrolled patients with medically uncontrolled glaucoma secondary to PPV with SO injection who underwent TSCPC using slow coagulation TSCPC settings (power of 1250 mW and duration of 4 s). The primary outcome measure was surgical success at 12 months.

--A total of 18 eyes of 18 patients were included in the study. The mean age and follow-up of the patients were 51.94±14.5 years and 16.3±3.5 months, respectively.

--The mean intraocular pressure decreased from 29.7±9.6 mm Hg preoperatively to 14.6±6.5 mm Hg at 12 months postoperatively.

--Glaucoma medications were reduced from 4.2±0.9 at baseline to 1.9±1.3 at 12 months after TSCPC.

--A nonsignificant change of logarithm of the minimum angle of resolution visual acuity was observed at 12 months.

--The success rate at 12 months was 72.2%. No major complications were reported during the first year of follow-up.

Finally, when performed as an initial glaucoma surgical treatment in patients with SO-induced glaucoma, slow coagulation TSCPC demonstrated a high efficacy and minimum risks.